Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect and assess information on safety and efficacy of fondaparinux in patients undergoing general surgery of the lower limb at high risk of developing venous thromboembolism.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fondaparinux; PENTA

Criteria

Inclusion Criteria:

• Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism

Exclusion Criteria:

• Patients with a history of hypersensitivity to the ingredients of fondaparinux

• Patients with bleeding (bleeding in important organs, sucn as retroperitoneal bleed)

• Patients with acute bacterial endocarditis

• Patients with severe renal impairment